Kadmon Holdings, Inc. (NYSE:KDMN) Files An 8-K Regulation FD DisclosureITEM 7.01
On September 25, 2017, Kadmon Holdings, Inc. (the “Company”) issued a press release announcing the commencement of a public offering of its common stock and warrants to purchase its common stock. A copy of the press release is furnished herewith as Exhibit 99.1 and incorporated in this Item 7.01 by reference.
The information in this Item 7.01, including Exhibit 99.1 hereto, is being “furnished” and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of Section 18 of the Exchange Act. The information in this Item 7.01 shall not be incorporated by reference into any registration statement or other document to the Securities Act of 1933, as amended, or into any filing or other document to the Exchange Act, except as otherwise expressly stated in any such filing.
This Current Report on Form 8-K, including the exhibits hereto, is for informational purposes only and does not constitute an offer to sell, or a solicitation of an offer to buy, nor shall there be any sale of the securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
On September 15, 2017, the Company released a corporate presentation, a copy of which is attached hereto as Exhibit 99.2 and incorporated by reference herein.
On September 13, 2017, the Company dosed the first patient in a Phase 1 clinical study to evaluate the safety and tolerability of tesevatinib in autosomal recessive polycystic kidney disease (“ARPKD”).
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits.
Kadmon Holdings, Inc. ExhibitEX-99.1 2 dp80729_ex9901.htm EXHIBIT 99.1 Exhibit 99.1 Kadmon Announces Proposed Public Offering of Common Stock and Warrants NEW YORK – September 25,…To view the full exhibit click here
About Kadmon Holdings, Inc. (NYSE:KDMN)
Kadmon Holdings, Inc. is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases. Its product pipeline consists of KD025, Tesevatinib and KD034. The Company’s other products include Ribasphere RibaPak, Ribasphere, Qsymia, Tetrabenazine and Valganciclovir. KD025 is an orally available, selective small molecule inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2), a molecular target in multiple autoimmune, fibrotic and neurodegenerative diseases. Tesevatinib is an oral tyrosine kinase inhibitor (TKI) designed to block key molecular drivers of tumor growth, metastases and drug resistance. KD034 is the Company’s portfolio of enhanced formulations of trientine hydrochloride for the treatment of Wilson’s disease.
